AMYT   $14.7  0.20% Market Closed

Amryt Pharma PLC
Last Events:

2023-03-30 Trend pattern changed from канал to восходящий треугольник.

2023-03-30 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-03-30 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-03-29 Trend pattern changed from восходящий треугольник to канал.

2023-03-29 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-03-29 Trend pattern changed from канал to восходящий треугольник.

2023-03-29 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: entrance to the overbought zone.

2023-03-28 Trend pattern changed from восходящий треугольник to канал.


Current temperature: 0.57
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 10.75
Target: 17.63
High with 50% probability: 19.46
Analyst Recommendations:
Number of estimates 4
Target Price Mean 17.63
Mean unverified/preliminary 17.63 / 17.63
Target Price Low / High 14.50 / 27.00
Median / STD DEV 14.50 / 6.25
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy Sell
rsi Sell - -
macd - - -
stoch - - -
ma20 Sell Sell Sell
ma50 - - -
ma100 ActivelyBuy ActivelyBuy -
Candlestick PatternApril 11, 2023 Bearish Harami - consists of an unusually large white body followed by a small black body contained within. Large white body It is considered as a bearish pattern when preceded by an uptrend.
ceo Dr. Joseph A. Wiley
Website https://www.amrytpharma.com
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.